Navigation Links
Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7

SUNNYVALE, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that it will host a webcast and conference call on, Tuesday, December 8, 2009 at 11:00am Eastern Time (10:00am Central Time and 8:00am Pacific Time) to discuss clinical data regarding its HDAC Program (PCI-24781) and its BTK Program (PCI-32765) that will be presented at the American Society of Hematology (ASH) meeting.

Date: December 8, 2009
Time: 11:00AM ET (10:00AM CT and 8:00AM PT)

Listen via Internet:

Toll-free: (877) 700-2945
International: (706) 643-1591
Conference ID: 45071660

A webcast replay will be available on the Pharmacyclics website for 30 days.

The following Posters will be presented at ASH:

Title: Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma

Date / Time:  Sunday, December 6, 2009, 6:00PM-8:00PM
Location:  Hall E (Ernest N. Morial Convention Center) Poster Board II-702
Poster Session: Lymphoma: Therapy with Biologic Agents, excluding Pre-
 Clinical Models Poster II
Primary presenter: Dr. Andrew Evens, Northwestern University

Title: A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay

Date / Time:  Monday, December 7, 2009, 6:00PM-8:00PM
Location:  Hall E (Ernest N. Morial Convention Center) Poster Board
Poster Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models
 Poster III
Primary presenter: Dr. Daniel Pollyea, Stanford University

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at

Ramses Erdtmann
Vice President of Finance
Phone: 408-215-3325

SOURCE Pharmacyclics, Inc.

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
2. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
3. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
4. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
5. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
8. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
9. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
10. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
11. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
Post Your Comments:
(Date:11/30/2015)... 2015 2014RestatedChange%Turnover 545,575 , 518,852 , 5.2 Cord Blood ... , 9.8 Hospital Management Service Income , ... Medical Insurance Administration Service Income , 2,780 , ... , 89,645 , 94,580 , ... 2,917 , (3.3) Gross Profit 395,857 , ...
(Date:11/30/2015)...  PTS Diagnostics, the U.S.-based manufacturer of point-of-care biometric ... ® systems, and PTS Detect™ cotinine systems, has ... will propel the company into the mHealth market. ... . The technology is a system that interfaces ... and tablets, and uses test strip technology already developed ...
(Date:11/30/2015)... Nov. 30, 2015 Cumberland Pharmaceuticals (CPIX), today announced that ... at on December 3, 2015. TIME: 3:15p.m. ... 3:15p.m. ET LINK: --> ... --> --> ... investors are invited to ask the company questions in real-time ...
Breaking Medicine Technology:
(Date:11/30/2015)... York (PRWEB) , ... November 30, 2015 , ... In ... of his role as a top ophthalmologist on Long Island’s east end. During the ... teaching, innovations in surgery and treatment of glaucoma and cataracts, and how a visit ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its ... specializing in independent living, assisted living and all other retirement options. Support for ... awareness and research remains a top priority. , So it’s no surprise ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of the leading plastic surgery practices in Florida, is proud to announce that ... for surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon ...
(Date:11/30/2015)... New York, New York (PRWEB) , ... November 30, 2015 , ... ... at the Greater New York Dental Meeting. Their Ecosystem empowers dentists to make complex ... Dentists who visit the booth will receive a free fee survey with 10 procedures ...
(Date:11/30/2015)... ... 30, 2015 , ... Vasont Systems, a top component content ... extension unites with Syncro Soft’s latest software update, oXygen XML editor Version 17.1. ... the latest release of oXygen® XML editor and the Vasont® CCMS. , ...
Breaking Medicine News(10 mins):